stock delisting
AnPac Bio Receives Nasdaq Delisting Notice
The Chinese cancer diagnostics firm plans to appeal the decision, which is related to a requirement that the firm maintain a minimum $2.5 million stockholders' equity.
AnPac Bio Receives Nasdaq Delisting Notice
The firm previously received notification from Nasdaq that it no longer met multiple minimum listing requirements for the exchange.
Interpace Biosciences Receives Nasdaq Delisting Notice, Initiates Restructuring
The notice was issued due to the company's extended period of non-compliance with the minimum $2.5 million stockholder's equity requirement for continued listing.
T2 Biosystems Regains Compliance With Nasdaq Listing Requirements
In April the firm received notice that it wasn't in compliance because its common stock didn't maintain a minimum bid price of $1.00 for 30 consecutive business days.
T2 Biosystems Receives Nasdaq Warning Letter
The Lexington, Massachusetts-based company also terminated a purchase agreement and raised the amount in it may raise in a public offering of its common stock to $95.